NOVAVAX INC NVAX

Latest FY: 2025 Healthcare Biotechnology
Market Price $8.05
Market Cap $1.34B
P/E Ratio 3.12
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑64.7% YoY
$1.12B
3-Yr CAGR: -17.2%
Net Income ↑334.8% YoY
$440.30M
Net Margin: 39.2%
Free Cash Flow ↓-149.4% YoY
-$250.19M
FCF Yield: -18.71%
EPS (Diluted) ↑309.8% YoY
$2.58
Basic: $2.72
Return on Equity Efficiency
N/A
ROA: 1,642.0%
⚡ N/A due to negative equity (share buybacks or other)

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (NVAX)

All monetary values in millions ($M)
⚠️ YoY Data Quality Alert
  • FY 2017: Revenue YoY (+103.1%) is identical to Gross Profit YoY (+103.1%). Verify the underlying Revenue and Gross Profit values for FY 2017 and FY 2016.
  • FY 2018: Revenue YoY (+10.0%) is identical to Gross Profit YoY (+10.0%). Verify the underlying Revenue and Gross Profit values for FY 2018 and FY 2017.
  • FY 2019: Revenue YoY (-45.6%) is identical to Gross Profit YoY (-45.6%). Verify the underlying Revenue and Gross Profit values for FY 2019 and FY 2018.
  • FY 2020: Revenue YoY (+2448.5%) is identical to Gross Profit YoY (+2448.5%). Verify the underlying Revenue and Gross Profit values for FY 2020 and FY 2019.
  • FY 2021: Revenue YoY (+141.0%) is identical to Gross Profit YoY (+141.0%). Verify the underlying Revenue and Gross Profit values for FY 2021 and FY 2020.
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $15.4M $9.7M $-280.0M $-1.03 $-255.5M $-273.7M
FY 2017 $31.2M +103.1% $19.7M $-183.8M +34.4% $-0.63 +38.8% $-138.7M $-142.9M +47.8%
FY 2018 $34.3M +10.0% $21.7M $-184.7M -0.5% $-0.50 +20.6% $-184.8M $-186.2M -30.3%
FY 2019 $18.7M -45.6% $11.8M $-132.7M +28.2% $-5.51 -1,002.0% $-136.6M $-138.5M +25.6%
FY 2020 $475.6M +2,448.5% $300.9M $-418.3M -215.2% $-7.27 -31.9% $-42.5M $-97.2M +29.8%
FY 2021 $1,146.3M +141.0% $725.2M $-1,743.8M -316.9% $-23.44 -222.4% $322.9M $265.5M +373.2%
FY 2022 $1,981.9M +72.9% $1,079.2M $-657.9M +62.3% $-8.42 +64.1% $-415.9M $-505.0M -290.2%
FY 2023 $983.7M -50.4% $639.9M $-545.1M +17.2% $-5.41 +35.7% $-714.0M $-767.7M -52.0%
FY 2024 $682.2M -30.7% $479.4M $-187.5M +65.6% $-1.23 +77.3% $-87.3M $-100.3M +86.9%
FY 2025 $1,123.5M +64.7% $1,050.4M $440.3M +334.8% $2.58 +309.8% $-244.6M $-250.2M -149.4%
$

Valuation

Market Price $8.05
Market Cap $1.34B
Enterprise Value N/A
P/E Ratio 3.12
P/B Ratio N/A
FCF Yield -18.71%
Dividend Yield N/A
Shares Outstanding 164,438,100
%

Profitability & Margins

Gross Margin 93.50%
Operating Margin 40.30%
Net Margin 39.19%
Return on Equity (ROE) N/A (Negative Equity)
Return on Assets (ROA) 1,642.00%
Asset Turnover 41.90x
Revenue 3-Yr CAGR -17.24%
🛡️

Financial Health & Liquidity

Current Ratio 0.25
Cash Ratio 2.25
Debt / Equity N/A
Debt / Assets N/A
Cash & Equivalents $240.63M
Total Debt N/A
Book Value / Share $-0.78
💧

Cash Flow Efficiency

Operating Cash Flow -$244.63M
Capital Expenditures (CapEx) $5.56M
Free Cash Flow -$250.19M
OCF / Revenue -21.77%
FCF / Revenue -22.27%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $2.58
EPS (Basic) $2.72
Dividends / Share N/A
Book Value / Share $-0.78
EPS YoY Growth 309.76%
🏛️

Balance Sheet (FY 2025)

Total Assets $26.82M
Total Liabilities $107.17M
Stockholders' Equity -$127.75M
Current Assets $26.82M
Current Liabilities $107.17M